Ultima Genomics Enhances Global Access to Affordable DNA Sequencing

Ultima Genomics Expands Access to DNA Sequencing

In a significant step towards democratizing genetic research, Ultima Genomics, Inc. has announced its ongoing commitment to improve global access to its groundbreaking UG 100™ next-generation sequencing platform. This initiative follows the establishment of partnerships with some of the premier genomic service providers around the world, enabling a wider audience of researchers to benefit from high-quality and low-cost DNA sequencing.

The UG 100™ sequencing platform is notable for its innovative architecture, designed to support a diverse range of genomics applications. This includes advanced techniques like single-cell sequencing, spatial transcriptomics, and proteomics, along with comprehensive whole-genome sequencing. The newly formed collaborations include esteemed organizations such as Broad Clinical Labs, Eurofins, Novogene, Psomagen, and the Ontario Institute of Cancer Research. These institutions join Ultima's existing network, which features notable partners such as Macrogen, Inocras, and the University of Minnesota Genomics Center.

Bridging the Gap in Genomic Research

Jay Therrien, the Chief Commercial Officer of Ultima Genomics, expressed enthusiasm for these new partnerships, highlighting their potential to broaden access to cutting-edge genomic technologies. "Our unique sequencing platform architecture supports a wide array of genomics applications while ensuring cost-effective solutions at an unprecedented scale," he stated.

This extensive network of service providers includes a variety of institutions ranging from leading academic research centers to clinical laboratories and commercial entities. The expansion aims to make low-cost sequencing services available across multiple regions, including the Asia-Pacific, EMEA (Europe, Middle East, and Africa), and the Americas. By doing so, Ultima Genomics hopes to stimulate advancements in key fields like AI/ML-enabled drug discovery and various omics research sectors.

Technological Breakthroughs with Solaris

Central to this expansion is the recent commercial launch of the UG 100 Solaris™. This new system utilizes innovative chemistry, optimized software, and streamlined workflows to significantly enhance sequencing output and efficiency. The Solaris technology enables a remarkable boost of more than 50% in output per sequencing run, achieving 10 to 12 billion reads per wafer. Additionally, it reduces sequencing costs by approximately 20%, bringing the price to just $0.24 per million reads, which translates to an astonishing $80 genome.

With these advancements, Ultima Genomics is set to transform the landscape of genomic research, making it accessible to a broader range of scientists and healthcare professionals. The company is determined to unleash the power of genomics at scale, driving essential progress in biological research and healthcare.

The Future of Genomic Information

Ultima Genomics positions itself uniquely in the field. Their mission revolves around enhancing the availability and affordability of genomic information, thereby facilitating groundbreaking progress in biology and human health. As the demand for genomic insights continues to surge, Ultima Genomics stands at the forefront, ready to challenge traditional next-generation sequencing methods and usher in the next major phase of genomic advancements.

With a vision that extends beyond conventional limits, Ultima Genomics is committed to harnessing the full potential of genomic data, accommodating the complexities and dynamic changes within biological systems. Researchers worldwide can look forward to a future where access to genomic information is no longer a limiting factor, but rather a catalyst for innovation and discovery.

To learn more about Ultima Genomics and their offerings, visit www.ultimagenomics.com.